DK1752465T3 - Lineær VH-CH1-VH-CH1 tung-kæde antistof-fragment - Google Patents

Lineær VH-CH1-VH-CH1 tung-kæde antistof-fragment

Info

Publication number
DK1752465T3
DK1752465T3 DK06022818.6T DK06022818T DK1752465T3 DK 1752465 T3 DK1752465 T3 DK 1752465T3 DK 06022818 T DK06022818 T DK 06022818T DK 1752465 T3 DK1752465 T3 DK 1752465T3
Authority
DK
Denmark
Prior art keywords
heavy chain
linear
antibody fragment
chain antibody
chain fragment
Prior art date
Application number
DK06022818.6T
Other languages
English (en)
Inventor
Ernst H Rinderknecht
Gerardo A Zapata
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1752465T3 publication Critical patent/DK1752465T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK06022818.6T 1995-04-20 1996-04-05 Lineær VH-CH1-VH-CH1 tung-kæde antistof-fragment DK1752465T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/425,763 US5641870A (en) 1995-04-20 1995-04-20 Low pH hydrophobic interaction chromatography for antibody purification
EP96912575A EP0821695B1 (en) 1995-04-20 1996-04-05 Antibody purification by low-ph hydrophobic interaction chromatography

Publications (1)

Publication Number Publication Date
DK1752465T3 true DK1752465T3 (da) 2011-08-15

Family

ID=23687930

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06022818.6T DK1752465T3 (da) 1995-04-20 1996-04-05 Lineær VH-CH1-VH-CH1 tung-kæde antistof-fragment
DK96912575T DK0821695T3 (da) 1995-04-20 1996-04-05 Oprensning af antistof ved hydrofob interaktionschromatografi ved lav pH-værdi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK96912575T DK0821695T3 (da) 1995-04-20 1996-04-05 Oprensning af antistof ved hydrofob interaktionschromatografi ved lav pH-værdi

Country Status (15)

Country Link
US (5) US5641870A (da)
EP (2) EP1752465B1 (da)
JP (3) JP4042868B2 (da)
AT (2) ATE510854T1 (da)
AU (1) AU721736B2 (da)
CA (1) CA2214633C (da)
DE (1) DE69636733T2 (da)
DK (2) DK1752465T3 (da)
ES (2) ES2365929T3 (da)
IL (1) IL117942A (da)
MX (1) MX9707909A (da)
NZ (2) NZ306718A (da)
PT (1) PT821695E (da)
WO (1) WO1996033208A1 (da)
ZA (1) ZA962885B (da)

Families Citing this family (1248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG43125A1 (en) * 1993-10-27 1997-10-17 Molex Inc Shunted electrical connector
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
AU2003200709B2 (en) * 1998-05-06 2006-06-29 Genentech, Inc. Protein purification
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
SI1308456T1 (sl) * 1998-05-06 2008-02-29 Genentech Inc Ciscenje protiteles z ionsko izmenjevalno kromatografijo
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
EP1191944A2 (en) 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
JP2001066308A (ja) * 1999-07-29 2001-03-16 Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh ＩｇＧ抗体の不可逆的損傷の検出
WO2001035735A1 (en) * 1999-11-19 2001-05-25 Hematech, Llc Production of ungulates, preferably bovines that produce human immunoglobulins
US7074983B2 (en) 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7820878B2 (en) * 1999-11-19 2010-10-26 Kyowa Hakko Kirin Co., Ltd. Production of ungulates, preferably bovines that produce human immunoglobulins
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
WO2001064711A1 (fr) * 2000-03-02 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Procede de separation et de purification de proteine
CN101289511A (zh) * 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
CA2411102A1 (en) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2424977C (en) * 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
KR100968664B1 (ko) * 2001-08-27 2010-07-06 제넨테크, 인크. 항체 발현 및 조립을 위한 시스템
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
NZ537328A (en) * 2002-05-31 2008-04-30 Genetic Technologies Ltd Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
ZA200501839B (en) * 2002-08-29 2006-10-25 Genentech Inc Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
US6967241B2 (en) * 2002-09-06 2005-11-22 Genentech, Inc. Process for protein extraction
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US20040138428A1 (en) * 2002-10-18 2004-07-15 Gerardo Zapata System and method for cleaving antibodies
WO2004044156A2 (en) * 2002-11-08 2004-05-27 Hematech, Llc Transgenic ungulates having reduced prion protein activity and uses thereof
JP2006517415A (ja) 2003-01-09 2006-07-27 ジェネンテック・インコーポレーテッド ポリペプチドの精製
WO2004078999A1 (en) * 2003-03-05 2004-09-16 Genetic Technologies Limited Identification of fetal dna and fetal cell markers in maternal plasma or serum
WO2004087761A1 (ja) * 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
AU2004251161A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
PL2784084T5 (pl) 2003-07-08 2024-12-02 Novartis Pharma Ag Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
WO2005037869A2 (en) * 2003-10-15 2005-04-28 Applera Corporation Method of reducing leachate from protein a affinity media
DE602004026343D1 (de) * 2003-10-24 2010-05-12 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20050214805A1 (en) * 2003-11-10 2005-09-29 Q-Rna, Inc. Methods of detection employing immuno-Q-Amp technology
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
US20060047436A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for magnifying an immune response
US20060047435A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to augmenting an immune system
US20060182742A1 (en) * 2004-08-24 2006-08-17 Ishikawa Muriel Y System and method for magnifying a humoral immune response
US20060047437A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for heightening an immune response
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
US20060047434A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to improving an immune system
US20060116824A1 (en) * 2004-12-01 2006-06-01 Ishikawa Muriel Y System and method for modulating a humoral immune response
US20060095211A1 (en) * 2003-12-05 2006-05-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for modulating a cell mediated immune response
WO2005073711A2 (en) * 2004-01-20 2005-08-11 Pall Corporation Chromatographic material for the absorption of proteins at physiological ionic strength
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
AR049021A1 (es) * 2004-04-16 2006-06-21 Genentech Inc Tratamiento de trastornos con un anticuerpo que se une a cd20
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
BRPI0508762A (pt) * 2004-04-16 2007-08-14 Genentech Inc método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição
NZ550106A (en) * 2004-04-22 2009-06-26 Kyowa Hakko Kirin Co Ltd Transgenic animals and uses thereof
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2006014729A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
US20070196362A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to bolster an immune response
US20070265819A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for improving cell-mediated immune response
US20070265787A1 (en) * 2004-08-24 2007-11-15 Searete Llc,A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for magnifying cell-mediated immune response
US20070265817A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to fortifying an immune system
US20070198196A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to ameliorating an immune system
US20070265788A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for augmenting cell-mediated immune response
US20070288173A1 (en) * 2004-08-24 2007-12-13 Searete Llc, A Limited Liability Corporation Of The State Of Delware Computational methods and systems to reinforce a humoral immune response
US20070207492A1 (en) * 2004-08-24 2007-09-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to adjust a humoral immune response
US20070265818A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20060047439A1 (en) * 2004-08-24 2006-03-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for improving a humoral immune response
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1802334T3 (pl) 2004-10-21 2013-01-31 Genentech Inc Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1841793B1 (en) 2005-01-07 2010-03-31 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
AU2006223180B2 (en) 2005-03-11 2011-11-24 Wyeth Llc A method of weak partitioning chromatography
WO2006109045A2 (en) 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2500356A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
WO2007038392A2 (en) * 2005-09-23 2007-04-05 Walter Reed Army Institute Of Research (Wrair) Antibodies with simultaneous subsite specificities to protein and lipid epitopes
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
DK2500360T3 (da) 2005-10-31 2015-10-26 Oncomed Pharm Inc Sammensætninger og fremgangsmåder til diagnosticering og behandling af cancer
WO2007056411A2 (en) * 2005-11-08 2007-05-18 Genentech, Inc. Method of producing pan-specific antibodies
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP1954719A2 (en) 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CA2633887C (en) 2005-12-15 2015-12-22 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US7625759B2 (en) * 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
AU2007248444B2 (en) 2006-01-05 2012-10-25 Genentech, Inc. Anti-EphB4 antibodies and methods using same
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
HRP20150884T1 (hr) 2006-03-21 2015-09-25 Genentech, Inc. Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
EP2389947A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
KR20140071452A (ko) 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
DE102006017701A1 (de) * 2006-04-15 2007-10-25 Degussa Gmbh Silicium-Titan-Mischoxidpulver, Dispersion hiervon und daraus hergestellter titanhaltiger Zeolith
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
US8124743B2 (en) * 2006-06-01 2012-02-28 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
CN101484471B (zh) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
JP2009543579A (ja) 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2061900A2 (en) 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2008027236A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
KR20140116546A (ko) 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
WO2008127305A2 (en) * 2006-11-01 2008-10-23 Biogen Idec Ma Inc. Method of isolating biomacromolecules using low ph and divalent cations
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US8444971B2 (en) 2006-11-27 2013-05-21 Diadexus, Inc. OVR110 antibody compositions and methods of use
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
NZ577933A (en) * 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
AR065271A1 (es) 2007-02-09 2009-05-27 Genentech Inc Anticuerpos anti-robo4 y sus usos
WO2008100578A2 (en) * 2007-02-14 2008-08-21 Amgen Inc. Method of isolating antibodies by precipitation
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
DK2134360T3 (da) 2007-03-14 2016-02-22 Takeda Vaccines Inc Oprensning af viruslignende partikel
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US8263081B2 (en) 2007-05-14 2012-09-11 The University Of Chicago Antibody-light fusion products for cancer therapeutics
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
DK2173379T3 (da) 2007-07-02 2015-12-07 Oncomed Pharm Inc Sammensætninger og fremgangsmåder til behandling og diagnosticering af cancer
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
KR20100058509A (ko) * 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
RU2010111120A (ru) 2007-08-24 2011-09-27 Онкотерапи Сайенс, Инк. (Jp) Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого
WO2009028521A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
JP5695905B2 (ja) 2007-10-02 2015-04-08 ジェネンテック， インコーポレイテッド Ｎｌｒｒ−１アンタゴニスト及びその使用
WO2009045897A1 (en) * 2007-10-03 2009-04-09 Dyax Corp. Systems and methods for purifying proteins
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
WO2009062102A2 (en) 2007-11-07 2009-05-14 Genentech, Inc. Compositions and methods for treatment of microbial disorders
NZ585500A (en) 2007-11-12 2012-06-29 Theraclone Sciences Inc Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2261367A3 (en) 2007-11-29 2011-03-23 Genentech, Inc. Gene expression markers for inflammatory bowel disease
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
GB0723797D0 (en) * 2007-12-05 2008-01-16 Immunosolv Ltd Method
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
ES2626634T3 (es) 2007-12-19 2017-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
WO2009111644A2 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
AU2009223688B2 (en) 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
AU2009236653B2 (en) * 2008-04-16 2014-09-25 Biogen Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
CA2723707C (en) 2008-05-09 2016-08-23 Akonni Biosystems Microarray system
US8680025B2 (en) * 2008-05-09 2014-03-25 Akonni Biosystems, Inc. Microarray system
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
AU2009266989B2 (en) * 2008-07-03 2013-05-02 Pfenex, Inc. High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
NZ603698A (en) * 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CN102143977B (zh) * 2008-09-03 2014-08-06 霍夫曼-拉罗奇有限公司 多特异性抗体
BRPI0918978A2 (pt) 2008-09-10 2015-12-01 Genentech Inc composições e métodos a prevenção da degradação oxidativa das proteínas
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
GB0818228D0 (en) 2008-10-06 2008-11-12 Avecia Biolog Ltd Purification process
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
PT2356462T (pt) 2008-11-11 2017-04-07 Univ Michigan Regents Composições e métodos anti-cxcr1
EP2346529B1 (en) * 2008-11-12 2016-02-10 Theraclone Sciences, Inc. Human m2e peptide immunogens
JP6018753B2 (ja) 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
KR101807319B1 (ko) 2008-11-22 2017-12-11 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
WO2010062858A1 (en) * 2008-11-26 2010-06-03 Allergan, Inc. Il-17 antibody inhibitor for treating dry eye
WO2010062857A1 (en) 2008-11-26 2010-06-03 Allergan, Inc. Klk-13 antibody inhibitor for treating dry eye
MX2011005953A (es) * 2008-12-04 2011-08-17 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2746330C (en) 2008-12-23 2017-08-29 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
JP5861223B2 (ja) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
EP2398829A2 (en) * 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
GB0903168D0 (en) 2009-02-25 2009-04-08 Fusion Antibodies Ltd Diagnostic method and kit
EP2403531A4 (en) 2009-03-05 2013-02-27 Abbott Lab IL-17 BINDING PROTEINS
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
TWI507205B (zh) 2009-03-25 2015-11-11 Genentech Inc 抗ｆｇｆｒ３抗體及使用方法
MY173526A (en) 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
JP5681166B2 (ja) 2009-03-31 2015-03-04 スリーエム イノベイティブ プロパティズ カンパニー 疎水性モノマー、疎水的に誘導体化された支持体、並びにその製造及び使用方法
TWI474833B (zh) 2009-04-01 2015-03-01 Genentech Inc 胰島素阻抗性疾病之治療
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
US9447467B2 (en) 2009-04-21 2016-09-20 Genetic Technologies Limited Methods for obtaining fetal genetic material
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP2012527473A (ja) 2009-05-20 2012-11-08 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
WO2010141630A1 (en) 2009-06-03 2010-12-09 University Of Southern California Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
CN102471381A (zh) 2009-07-07 2012-05-23 霍夫曼-拉罗奇有限公司 自身免疫性脱髓鞘疾病的诊断和治疗
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
CN102639710A (zh) 2009-07-20 2012-08-15 基因泰克公司 克罗恩病的基因表达标记
JP5665866B2 (ja) 2009-07-24 2015-02-04 アコーニ バイオシステムズＡｋｏｎｎｉ Ｂｉｏｓｙｓｔｅｍｓ フローセルデバイス
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
RU2567803C2 (ru) 2009-07-31 2015-11-10 Дженентек, Инк. ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
BR112012003346A2 (pt) 2009-08-15 2016-11-16 Genentech Inc metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DK2473522T3 (da) 2009-09-02 2016-11-28 Genentech Inc Smoothened-mutant og fremgangsmåder til anvendelse af samme
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
AU2010297344A1 (en) 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
MX337666B (es) 2009-10-20 2016-03-14 Nestec Sa Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
EP2491059B1 (en) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2776990A1 (en) 2009-10-30 2011-05-05 Abbott Laboratories Sorf constructs and multiple gene expression
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
BR112012010153B1 (pt) * 2009-11-05 2022-05-03 Genentech, Inc Método de produção de um anticorpo
BR112012012750A2 (pt) 2009-11-30 2020-08-11 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado e método
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
JP6214161B2 (ja) 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
GB0922553D0 (en) 2009-12-23 2010-02-10 Fusion Antibodies Ltd Prognostic marker
RU2559542C2 (ru) 2009-12-23 2015-08-10 Дженентек, Инк. Антитела против bv8 и их применение
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
EP2528944B1 (en) 2010-01-29 2015-08-12 MorphoSys AG Rodent combinatorial antibody libraries
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
TWI429453B (zh) 2010-02-23 2014-03-11 建南德克公司 抗tat419抗體及其用途
KR102104197B1 (ko) 2010-02-23 2020-04-24 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
SG183542A1 (en) 2010-03-12 2012-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
CN104998269B (zh) 2010-03-22 2019-06-11 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
CN103068378B (zh) 2010-05-10 2016-07-06 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
KR101539684B1 (ko) 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
WO2011156369A2 (en) * 2010-06-07 2011-12-15 Dr. Reddy's Laboratories Ltd. Purification of modified cytokines
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
WO2012021786A2 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EP2606334B1 (en) * 2010-08-20 2018-04-25 GE Healthcare Limited Quality control cassette and method for radiopharmaceuticals
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
CA3249351A1 (en) 2010-08-31 2025-07-03 Theraclone Sciences, Inc. Neutralizing antibodies against human immunodeficiency viruses (HIV)
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012032043A1 (en) 2010-09-07 2012-03-15 Areva Med Llc 212 pb imaging
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP3223014B1 (en) * 2010-09-24 2018-12-05 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
WO2012061129A1 (en) 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012075333A2 (en) 2010-12-02 2012-06-07 Prometheus Laboratories Inc. Her2delta16 peptides
CN103517921B (zh) 2010-12-21 2017-07-18 Abbvie 公司 IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2012084272A1 (en) 2010-12-23 2012-06-28 Intercell Ag Oprf/i agents and their use in hospitalized and other patients
EP2656077A1 (en) 2010-12-23 2013-10-30 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
AU2012205718B2 (en) 2011-01-10 2017-07-06 The Regents Of The University Of Michigan Stem cell factor inhibitor
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP2014506580A (ja) 2011-02-14 2014-03-17 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP6385060B2 (ja) 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療的に活性な抗体のインビボにおける選択
US20140099264A1 (en) 2011-03-07 2014-04-10 F. Hoffman-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
KR20190107761A (ko) 2011-03-09 2019-09-20 셀 시그널링 테크놀러지, 인크. 모노클로날 항체를 생성하는 방법 및 시약
SG193402A1 (en) 2011-03-15 2013-10-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
ES2685079T3 (es) 2011-03-25 2018-10-05 F. Hoffmann-La Roche Ag Procedimientos de purificación de proteínas novedosos
EP3412309A1 (en) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Methods of administering beta7 integrin antagonists
HK1200329A1 (en) 2011-04-25 2015-08-07 先进生物学实验室股份有限公司 Truncated hiv envelope proteins (env), methods and compositions related thereto
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2702408A1 (en) 2011-04-29 2014-03-05 Novartis AG Methods of treating squamous cell carcinoma related applications
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP2014518624A (ja) 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー ニューログラニン診断キットのためのアッセイ試薬
EA032929B1 (ru) 2011-05-17 2019-08-30 Дзе Рокфеллер Юниверсити Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
WO2013001080A1 (en) 2011-06-30 2013-01-03 Gene Signal International Sa Composition comprising inhibitors of irs-1 and of vegf
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
AP2014007415A0 (en) 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
EP2736532B1 (en) 2011-07-25 2018-05-16 California Institute of Technology Compositions and methods for improving potency and breadth or hiv antibodies
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
CA2842481A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
CN107266577B (zh) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
EP2581388A1 (en) 2011-10-14 2013-04-17 Centre National de la Recherche Scientifique (CNRS) Anti-sPLA2-V antibodies and uses thereof
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
AU2012328917B2 (en) 2011-10-24 2017-05-25 Abbvie Inc. Bispecific immunobinders directed against TNF and IL-17
BR112014010406A2 (pt) 2011-11-02 2017-04-25 Genentech Inc cromatografia de sobrecarga e eluto
JP6180425B2 (ja) 2011-11-23 2017-08-23 メディミューン，エルエルシー Ｈｅｒ３に特異的な結合分子及びそれらの使用
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
EP2602265A1 (en) 2011-12-07 2013-06-12 Centre National de la Recherche Scientifique (CNRS) Antibodies anti-sPLA2-X and uses thereof
JP2015501839A (ja) 2011-12-15 2015-01-19 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
RU2648999C2 (ru) * 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
KR101721678B1 (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
EP2641916A1 (en) 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
EP2830659A1 (en) 2012-03-27 2015-02-04 Novartis AG Treatment of fibrosis
EP2833900B1 (en) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EP2855520B1 (en) 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
AP2014008145A0 (en) 2012-06-08 2014-12-31 Glenmark Pharmaceuticals Sa Humanized anti-trkA antibodies with animo acid substitutions
WO2013192589A1 (en) 2012-06-21 2013-12-27 California Institute Of Technology Antibodies targeting hiv escape mutants
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US9297806B2 (en) 2012-08-01 2016-03-29 The Johns Hopkins University 5-hydroxymethylcytosine in human cancer
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
HUE049693T2 (hu) 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014040025A2 (en) 2012-09-10 2014-03-13 International Aids Vaccine Initiative Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
CA2887037A1 (en) 2012-10-02 2014-04-10 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activated matriptase
LT2908912T (lt) 2012-10-18 2020-09-25 The Rockefeller University Plačiai neutralizuojantys anti-živ antikūnai
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
CN105051528A (zh) 2012-11-15 2015-11-11 弗·哈夫曼-拉罗切有限公司 离子强度介导的pH梯度离子交换色谱
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
HUE053669T2 (hu) 2012-12-05 2021-07-28 Novartis Ag Készítmények és eljárások EPO-t célzó antitestekre
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
WO2014116596A1 (en) 2013-01-22 2014-07-31 Abbvie, Inc. Methods for optimizing domain stability of binding proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
KR102447350B1 (ko) 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
CA2901126C (en) 2013-02-25 2022-01-25 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
WO2014142117A1 (ja) 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
IL269947B (en) 2013-03-13 2022-08-01 Genentech Inc Formulations with reduced oxidation
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
PL2968467T3 (pl) 2013-03-13 2020-10-19 F. Hoffmann-La Roche Ag Preparaty o zmniejszonym utlenianiu
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
CN113549148B (zh) 2013-03-14 2025-11-21 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
EP2968544A4 (en) 2013-03-15 2016-10-12 Hoffmann La Roche CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
SI2970875T2 (sl) 2013-03-15 2026-03-31 F. Hoffmann-La Roche Ag Sestavki celičnih kultur z antioksidanti in postopki za proizvodnjo polipeptidov
DK2970378T3 (da) * 2013-03-15 2021-08-23 Biogen Ma Inc Hydrofob interaktionsproteinkromatografi under saltfrie betingelser
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
KR102175688B1 (ko) 2013-03-27 2020-11-06 제넨테크, 인크. 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
RU2646098C2 (ru) 2013-04-30 2018-03-01 Интас Фармасьютикалс Лтд Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
SG11201509371XA (en) 2013-05-24 2015-12-30 Nestec Sa Pathway specific markers for diagnosing irritable bowel syndrome
EP3008201B1 (en) 2013-06-12 2019-08-07 The General Hospital Corporation Methods for multiplexed detection of target molecules and uses thereof
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
AU2014287044B2 (en) 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
RU2016112549A (ru) 2013-09-05 2017-10-10 Дженентек, Инк. Способ для повторного использования хроматографии
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
MX2016003256A (es) 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
AU2014391422A1 (en) 2013-09-17 2015-12-17 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
MX375378B (es) 2013-09-27 2025-03-06 Genentech Inc Formulaciones de anticuerpos anti-pdl1.
US9243294B2 (en) 2013-09-30 2016-01-26 Hadasit Medical Research Services And Development Ltd. Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
ES2808684T3 (es) 2013-11-25 2021-03-01 Famewave Ltd Composiciones que incluyen anticuerpos anti-ceacam1 y anti-pd para terapia de cáncer
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
KR102311761B1 (ko) 2013-12-09 2021-10-13 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
BR112016012538A2 (pt) 2013-12-17 2017-09-26 Novartis Ag peptídeos citotóxicos e conjugados dos mesmos
EP3083682B1 (en) 2013-12-20 2024-04-17 F. Hoffmann-La Roche AG Dual specific antibodies
US10188650B2 (en) 2014-01-03 2019-01-29 The Regents Of The University Of Michigan Treatment of neurological disorders
EP2891657A1 (en) 2014-01-07 2015-07-08 Centre National de la Recherche Scientifique (CNRS) Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP2896400A1 (en) 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
PL3107554T3 (pl) 2014-02-19 2020-12-28 University Of Tennessee Research Foundation Przeciwciało dla odchylenia proporcji płci i sposoby jego zastosowania
CA2939931C (en) 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
CA2940451A1 (en) 2014-03-12 2015-09-17 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
EP3116999B1 (en) 2014-03-14 2021-09-15 F. Hoffmann-La Roche AG Methods and compositions for secretion of heterologous polypeptides
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
HUE051676T2 (hu) 2014-04-08 2021-03-29 Boston Pharmaceuticals Inc Il-21-re specifikus kötõ molekulák és alkalmazásaik
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
CA2983796A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN106573977B (zh) 2014-04-27 2020-08-07 菲姆威有限公司 针对ceacam1的人源化抗体
CA2943707A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko) 2014-05-27 2023-03-21 아카데미아 시니카 항-ｈｅｒ2 글리코항체 및 이의 용도
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
KR102366644B1 (ko) 2014-05-30 2022-02-22 상하이 헨리우스 바이오테크, 인크. 항-표피 성장 인자 수용체 (egfr) 항체
WO2015191760A2 (en) 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
CN106573956A (zh) 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
ES2694296T3 (es) 2014-06-17 2018-12-19 Centre National De La Recherche Scientifique (Cnrs) Anticuerpos monoclonales anti-pVHL y usos de los mismos
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
EP3978524A1 (en) 2014-07-03 2022-04-06 Yale University Dickkopf2 (dkk2) inhibition suppresses tumor formation
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
CN106536540A (zh) 2014-07-24 2017-03-22 基因泰克公司 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
KR20170040249A (ko) 2014-08-12 2017-04-12 노파르티스 아게 항-cdh6 항체 약물 접합체
WO2016033331A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
HRP20190881T1 (hr) 2014-08-28 2019-07-12 Halozyme, Inc. Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
WO2016044697A1 (en) 2014-09-19 2016-03-24 The Johns Hopkins University Biomarkers of cognitive dysfunction
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
HUE070383T2 (hu) 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
MX382952B (es) 2014-11-05 2025-03-13 Genentech Inc Métodos de producción de proteínas de cadena doble en bacterias.
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
DK3218406T4 (da) 2014-11-10 2024-12-09 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
EP3217787B1 (en) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Animal model for nephropathy and agents for treating the same
EP3218407A1 (en) 2014-11-11 2017-09-20 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
US9526768B2 (en) 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
SG11201703729RA (en) 2014-11-19 2017-06-29 Nestec Sa Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
EP3221445B1 (en) 2014-11-20 2021-07-14 The Regents of The University of California Compositions and methods related to hematologic recovery
EP3227446A1 (en) 2014-12-01 2017-10-11 Novartis AG Compositions and methods for diagnosis and treatment of prostate cancer
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
EP3029032A1 (en) 2014-12-05 2016-06-08 Centre National de la Recherche Scientifique (CNRS) Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
US20160158360A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
US10703813B2 (en) 2014-12-19 2020-07-07 Universite De Nantes Anti IL-34 antibodies
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
SG11201704741PA (en) 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
EP3244926B8 (en) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP2018510844A (ja) 2015-01-24 2018-04-19 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
CA2973886A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
KR20170138410A (ko) 2015-02-23 2017-12-15 시걸 테라퓨틱스 에스에이에스 비-천연 세마포린 3 및 이의 의학적 용도
AU2016222830B2 (en) 2015-02-24 2021-02-25 Bioatla Llc Conditionally active biological proteins
NZ733854A (en) 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
KR20170120601A (ko) 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
KR20170122216A (ko) 2015-03-06 2017-11-03 제넨테크, 인크. 초순수화 dsba 및 dsbc와 이를 제조하고 사용하는 방법
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016157195A1 (en) 2015-04-01 2016-10-06 Hadasit Medical Research Services And Development Ltd. Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
HK1249534A1 (zh) 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
WO2016164799A1 (en) 2015-04-10 2016-10-13 The Regents Of The University Of California Methods of determining patient populations amenable to immunomodulatory treatment of cancer
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
EP3286315B1 (en) 2015-04-24 2021-05-26 F. Hoffmann-La Roche AG Methods of identifying bacteria comprising binding polypeptides
WO2016183104A1 (en) 2015-05-11 2016-11-17 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2016191397A1 (en) 2015-05-22 2016-12-01 Td2 Inc. Benzamide and active compound compositions and methods of use
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
CN107646038B (zh) 2015-05-28 2021-08-20 基因泰克公司 用于检测抗cd3同二聚体的基于细胞的测定
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
CA2982237A1 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3302525A2 (en) 2015-06-05 2018-04-11 Novartis AG Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
PH12017501857B1 (en) 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
EP3334446A4 (en) 2015-06-17 2019-06-19 International Aids Vaccine Initiative MANIPULATED OUTER DOMAIN OF HV-GP120 MUTANES AND USE THEREOF
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
JP6896650B2 (ja) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
KR20180021864A (ko) 2015-06-29 2018-03-05 제넨테크, 인크. 장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
ES2887273T3 (es) 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
WO2017023866A1 (en) 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
CA3185706C (en) 2015-08-03 2025-11-18 Novartis Ag METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH FGF21
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
KR20180050339A (ko) 2015-09-04 2018-05-14 오비아이 파머 인코퍼레이티드 글리칸 어레이 및 사용 방법
JP6516925B2 (ja) 2015-09-09 2019-05-22 ノバルティス アーゲー 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
WO2017044694A2 (en) 2015-09-11 2017-03-16 The Board Of Trustrees Of The Leland Stanford Junior University Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
AU2016326738B2 (en) 2015-09-24 2023-08-31 Abvitro Llc HIV antibody compositions and methods of use
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
EP4732904A2 (en) 2015-10-06 2026-04-29 F. Hoffmann-La Roche AG Method for treating multiple sclerosis
AU2016334051B2 (en) 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
EP3362093A4 (en) 2015-10-13 2019-05-08 Technion Research & Development Foundation Limited HEPARANASE-NEUTRALIZING MONOCLONAL ANTIBODIES
LT3370515T (lt) 2015-10-21 2022-05-10 Redcoat Solutions, Inc. Patalinių blakių aptikimo įrenginys
ES2953484T3 (es) 2015-10-21 2023-11-13 Redcoat Solutions Inc Anticuerpos monoclonales antichinches y métodos de elaboración y usos de los mismos
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EP3368567B1 (en) 2015-10-28 2025-10-01 Yale University Humanized anti-dkk2 antibody and uses thereof
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
SMT202000285T1 (it) 2015-11-10 2020-07-08 Medimmune Llc Molecole di legame specifiche per asct2 e loro usi
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
WO2017089593A1 (en) 2015-11-26 2017-06-01 Universite Paris Descartes Inhibitors for treating or preventing a pulmonary arterial hypertension in systemic sclerosis patients and method for diagnosing said disease
UA125819C2 (uk) 2015-12-15 2022-06-15 Гіліад Сайєнсіз, Інк. ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
EP3389711A1 (en) 2015-12-18 2018-10-24 Novartis AG Antibodies targeting cd32b and methods of use thereof
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
EP3397243A1 (en) 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Use of tryptophan derivatives for protein formulations
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
JP6949030B2 (ja) 2016-01-08 2021-10-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
CN116003593A (zh) 2016-01-11 2023-04-25 苏黎世大学 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
CA3014842A1 (en) 2016-02-19 2017-08-24 Morphosys Ag Antibodies for il-17c
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
AU2017226955B2 (en) 2016-03-04 2023-03-16 Morphosys Ag Polypeptide library
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
JP6987072B2 (ja) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用
CN116196412A (zh) 2016-03-15 2023-06-02 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CN109153726A (zh) 2016-03-23 2019-01-04 普希克斯私人有限公司 抗因子xi的活性位点的单克隆抗体及其用途
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3018253A1 (en) 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
CN109379889A (zh) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
CN116751298A (zh) 2016-05-13 2023-09-15 生物蛋白有限公司 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
AU2017269675A1 (en) 2016-05-26 2019-01-17 Merck Patent Gmbh PD-1 / PD-L1 inhibitors for cancer treatment
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
US10851159B2 (en) 2016-06-02 2020-12-01 Bloom Diagnostics Ag Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
EP3471759A1 (en) 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CN109563124A (zh) 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化
EP3263706A1 (en) 2016-06-28 2018-01-03 Centre National De La Recherche Scientifique (Cnrs) Agents targeting snat7 for treating cellular metabolism reprogramming-associated diseases
LT3263715T (lt) 2016-06-28 2020-06-25 Hifibio Pavienių ląstelių transkriptomo analizės būdas
WO2018011691A1 (en) 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
BR112019001693A2 (pt) 2016-07-29 2019-07-02 INSERM (Institut National de la Santé et de la Recherche Médicale) anticorpos direcionados a macrófagos associados a tumores e seus usos
WO2018023121A1 (en) 2016-07-29 2018-02-01 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
WO2018026969A2 (en) 2016-08-03 2018-02-08 Achaogen, Inc. Plazomicin antibodies and methods of use
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
WO2018029586A1 (en) 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
HUE071741T2 (hu) 2016-08-15 2025-09-28 Hoffmann La Roche Nem-ionos felületaktív anyag mennyiségi meghatározására szolgáló kromatográfiás eljárás a nem-ionos felületaktív anyagot és polipeptidet tartalmazó összetételben
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
KR102579047B1 (ko) 2016-08-31 2023-09-14 온코세라피 사이언스 가부시키가이샤 MELK에 대한 단클론 항체(monoclonal antibody) 및 그 사용
US20190202907A1 (en) 2016-09-02 2019-07-04 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
US20190225682A1 (en) 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
RU2766233C2 (ru) 2016-09-06 2022-02-10 Чугаи Сейяку Кабусики Кайся Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018052818A1 (en) 2016-09-16 2018-03-22 Henlix, Inc. Anti-pd-1 antibodies
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US20190225701A1 (en) 2016-09-26 2019-07-25 The Brigham And Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I-Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EA201990986A1 (ru) 2016-10-25 2019-09-30 Ридженерон Фармасьютикалз, Инк. Способы и системы анализа хроматографических данных
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
US20180245065A1 (en) 2016-11-01 2018-08-30 Novartis Ag Methods and compositions for enhancing gene editing
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3544601B1 (en) 2016-11-23 2024-03-20 Translational Drug Development, LLC A composition comprising a benzamide and a tnfrsf agonist binding to 4-1bb or gitr, and the use thereof in the treatment of cancer.
US20230192896A1 (en) 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
US10852271B2 (en) 2016-12-14 2020-12-01 Taiwan Semiconductor Manufacturing Co., Ltd. On-chip heater
AU2017378451A1 (en) 2016-12-15 2019-07-04 The National Institute for Biotechnology in the Negev Ltd. Anti-PCNA monoclonal antibodies and use thereof
EP3555120A1 (en) * 2016-12-19 2019-10-23 Abcam Plc Monovalent and divalent binding proteins
CA3045592A1 (en) 2016-12-21 2018-06-28 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CN110325211A (zh) 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
PE20191548A1 (es) 2017-02-10 2019-10-24 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
CN108456251A (zh) 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
LT3375889T (lt) 2017-03-17 2020-06-25 Hifibio Sas Vienos ląstelės analizė
US12161694B2 (en) 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
SG10202110707UA (en) 2017-03-30 2021-11-29 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US11583588B2 (en) 2017-05-05 2023-02-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (SADA) technologies
KR20200016232A (ko) 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018234438A1 (en) 2017-06-22 2018-12-27 Morphosys Ag Canine antibody libraries
JP2020525019A (ja) 2017-06-27 2020-08-27 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 白血病におけるｃｔｌａ４アンタゴニストに対する耐性を同定および治療するための組成物および方法
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019018729A1 (en) 2017-07-20 2019-01-24 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
WO2019020807A1 (en) 2017-07-28 2019-01-31 Gene Signal International Sa CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
WO2019023525A1 (en) 2017-07-28 2019-01-31 Dana-Farber Cancer Institute, Inc. ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
CN111295394B (zh) 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
SG11202001348WA (en) 2017-09-05 2020-03-30 Immunogen Inc Methods for detection of folate receptor 1 in a patient sample
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
CA3076261A1 (en) 2017-09-19 2019-03-28 Admare Vintageco1 Investments Ltd. Anti-hla-a2 antibodies and methods of using the same
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
EP3684822A4 (en) 2017-09-20 2021-06-16 The University of British Columbia NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
US20230203149A1 (en) 2017-09-25 2023-06-29 Morphosys Ag Treatment of atopic dermatitis
EP3688007B1 (en) 2017-09-27 2024-07-31 The University of York Bioconjugation of polypeptides
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
EP3695408B1 (en) 2017-10-02 2026-01-21 The Broad Institute, Inc. Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
AU2018348430B2 (en) 2017-10-10 2025-09-04 Numab Therapeutics AG Antibodies targeting PDL1 and methods of use thereof
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
EP3470429A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN111183159B (zh) 2017-10-10 2024-09-03 努玛治疗有限公司 靶向cd137的抗体及其使用方法
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
JP2020536967A (ja) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
WO2019079362A1 (en) 2017-10-16 2019-04-25 Massachusetts Institute Of Technology HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
AU2018361430B2 (en) * 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
KR20200087236A (ko) 2017-11-22 2020-07-20 노파르티스 아게 항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도
WO2019102456A1 (en) 2017-11-27 2019-05-31 University Of Rijeka Faculty Of Medicine Immunotoxins for treating cancer
US11911123B2 (en) 2017-11-30 2024-02-27 The Johns Hopkins University Body mountable robot
JP7685835B2 (ja) 2017-12-01 2025-05-30 ノバルティス アーゲー ポリオーマウイルス中和抗体
WO2019113506A1 (en) 2017-12-07 2019-06-13 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
JP7774283B2 (ja) 2017-12-19 2025-11-21 ザ ロックフェラー ユニバーシティー エフェクター機能を改良したヒトＩｇＧのＦｃ領域改変体
CN111491951B (zh) 2017-12-22 2024-05-24 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
KR102845020B1 (ko) 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
JP7490565B2 (ja) 2017-12-29 2024-05-27 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019160976A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
CN111836831A (zh) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
US11485782B2 (en) 2018-03-14 2022-11-01 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US12139534B2 (en) 2018-03-15 2024-11-12 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
CR20250325A (es) 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
AU2019254483B2 (en) 2018-04-16 2025-02-27 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
US20210386829A1 (en) 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
CN112512576A (zh) 2018-05-04 2021-03-16 默克专利有限公司 PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
KR102892725B1 (ko) 2018-05-09 2025-12-01 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 넥틴4에 특이적인 항체
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
EP4474391A3 (en) 2018-05-14 2025-02-26 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
KR20210013090A (ko) 2018-05-16 2021-02-03 모르포시스 아게 당단백질 vi를 표적으로 하는 항체
AU2019274782A1 (en) 2018-05-24 2020-12-03 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
EP3802602A1 (en) 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
EP3802604A1 (en) 2018-05-31 2021-04-14 Glyconex Inc. Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
TW202014209A (zh) 2018-06-20 2020-04-16 瑞士商諾華公司 用於消融造血幹細胞之抗體藥物軛合物
CN112585166A (zh) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
CN112384532B (zh) 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
JP7535495B2 (ja) 2018-07-27 2024-08-16 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
CA3106537A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
US12097219B2 (en) 2018-09-10 2024-09-24 Legend Biotech Ireland Limited Single-domain antibodies against CLL1 and constructs thereof
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
EP3849602A1 (en) 2018-09-10 2021-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
WO2020056145A1 (en) 2018-09-14 2020-03-19 The Rockefeller University Anti-hiv antibody 10-1074 variants
KR102739487B1 (ko) 2018-09-21 2024-12-10 제넨테크, 인크. 3중-음성 유방암에 대한 진단 방법
WO2020064971A1 (en) 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
US10955379B2 (en) 2018-09-27 2021-03-23 Taiwan Semiconductor Manufacturing Co., Ltd. Differential sensing with BioFET sensors
WO2020069498A1 (en) 2018-09-28 2020-04-02 Jochen Reiser Supar and prediction and treatment of acute kidney injury
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
WO2020076849A1 (en) 2018-10-11 2020-04-16 The Scripps Research Institute Antibody compounds with reactive arginine and related antibody drug conjugates
US20220411783A1 (en) 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
EP3866785A1 (en) 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
CA3118453A1 (en) 2018-11-02 2020-05-07 The Regents Of The University Of California Compositions and methods for treating brain injury
WO2020096959A1 (en) 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive
US12402610B2 (en) 2018-11-09 2025-09-02 The Broad Institute, Inc. Methods and compositions for modulating innate lymphoid cell pathogenic effectors
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
GB201818618D0 (en) 2018-11-15 2019-01-02 Amlo Biosciences Ltd Monoclonal antibodies against ambra-1
GB201818622D0 (en) 2018-11-15 2019-01-02 Amlo Biosciences Ltd Monoclonal antibodies against loricrin
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
BR112021009554A2 (pt) 2018-12-03 2021-08-17 Eirion Therapeutics, Inc. aplicação melhorada de agentes grandes
JP2022513708A (ja) 2018-12-05 2022-02-09 モルフォシス・アーゲー 多重特異性抗原結合分子
MY207205A (en) 2018-12-07 2025-02-06 Shanghai hengrui pharmaceutical co ltd Cd3 antibody and pharmaceutical use thereof
CN113194925B (zh) 2018-12-14 2025-03-07 莫佛塞斯公司 抗体制剂
US20220064311A1 (en) 2018-12-18 2022-03-03 Catapult Therapeutics B.V. The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
EP3898700A1 (en) 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
WO2020132231A1 (en) 2018-12-21 2020-06-25 Genentech, Inc. Methods of producing polypeptides using a cell line resistant to apoptosis
KR20210109552A (ko) 2018-12-21 2021-09-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이중특이적 단백질
JP7607564B2 (ja) 2018-12-21 2024-12-27 ノバルティス アーゲー Ｐｍｅｌ１７に対する抗体及びその結合体
KR20210108421A (ko) 2018-12-24 2021-09-02 사노피 돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
BR112021012536A2 (pt) 2018-12-26 2021-09-14 City Of Hope Proteínas de ligação anti-ctla4 mascaradas ativáveis
CN113227135B (zh) 2018-12-28 2025-03-21 斯帕克斯治疗公司 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US12545727B2 (en) 2019-01-13 2026-02-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human Nectin-2
TW202515617A (zh) 2019-01-14 2025-04-16 美商建南德克公司 用於癌症療法之rna分子
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
KR20210133237A (ko) 2019-02-27 2021-11-05 제넨테크, 인크. 항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
WO2020180591A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
WO2020177733A1 (zh) 2019-03-06 2020-09-10 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020183473A1 (en) 2019-03-14 2020-09-17 Biond Biologics Ltd. Small shedding blocking agents
WO2020186235A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
MA55285A (fr) 2019-03-14 2022-01-19 Morphosys Ag Anticorps ciblant c5ar
EP3938394A1 (en) 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
US20220185875A1 (en) 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CN113631573B (zh) 2019-03-25 2024-06-04 国家医疗保健研究所 抗Tau抗体及其在制备用于治疗疾病的药物中的用途
BR112021019612A2 (pt) 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
WO2020215020A1 (en) 2019-04-18 2020-10-22 Qlsf Biotherapeutics Inc. Humanized anti-pd-l1 antibodies
WO2020214963A1 (en) 2019-04-18 2020-10-22 Genentech, Inc. Antibody potency assay
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
CA3135531A1 (en) 2019-04-30 2020-11-05 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
CN114269376A (zh) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 用抗pd-l1抗体治疗癌症的方法
GB201906297D0 (en) 2019-05-03 2019-06-19 Amlo Biosciences Ltd Biomarkers for disease progression in squamous cell carcinoma
GB201906302D0 (en) 2019-05-03 2019-06-19 Amlo Biosciences Ltd Methods of determining the margin of a tumour
MX2021013101A (es) 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
CA3139346A1 (en) 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
CA3139983A1 (en) 2019-05-14 2020-11-19 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
WO2020232262A1 (en) 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
EP3821250B1 (en) 2019-05-16 2022-05-04 ProciseDx Inc. An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
JP2022534227A (ja) 2019-05-23 2022-07-28 プロサイセデクス インコーポレイティド ヒト血清アルブミン、ビタミンｄ、ｃ反応性タンパク質、及び抗トランスグルタミナーゼ自己抗体の検出のためのアッセイ方法
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
US12066432B2 (en) 2019-06-05 2024-08-20 Gynuity Health Projects, Inc. Placental protein biomarkers for gestational age assessment and related methods
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
WO2020247159A1 (en) 2019-06-06 2020-12-10 Procisedx Inc. DETECTION OF HEMOGLOBIN A1C (HbA1c) IN BLOOD
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
EA202193345A1 (ru) 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
KR20220024729A (ko) 2019-06-24 2022-03-03 노파르티스 아게 B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
EP3990922A1 (en) 2019-06-25 2022-05-04 ProciseDx Inc. Detection of anti-tnf alpha drug biologics and anti-drug antibodies
EP3989937A1 (en) 2019-06-28 2022-05-04 Genentech, Inc. Composition and methods for stabilizing liquid protein formulations
EP3996816A1 (en) 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
WO2021005232A1 (en) 2019-07-11 2021-01-14 Umc Utrecht Holding B.V. Intranasal administration of neutralising antiviral antibodies
JPWO2021010326A1 (da) 2019-07-12 2021-01-21
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
CN114787373A (zh) 2019-07-25 2022-07-22 免疫苏醒公司 测量通过效应子进行的细胞介导的杀伤的方法
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
MX2022001260A (es) 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
GB201911210D0 (en) 2019-08-06 2019-09-18 Amlo Biosciences Ltd Clinical management of oropharyngeal squamous cell carcinoma
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021046159A1 (en) 2019-09-04 2021-03-11 Genentech, Inc. Cd8 binding agents and uses thereof
CA3153700A1 (en) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
US12235262B1 (en) 2019-09-09 2025-02-25 10X Genomics, Inc. Methods and systems for single cell protein analysis
WO2021050217A1 (en) 2019-09-11 2021-03-18 Imcare Biotech, Llc. Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
WO2021050645A1 (en) 2019-09-12 2021-03-18 Genentech, Inc. Compositions and methods of treating lupus nephritis
CA3154653A1 (en) 2019-09-17 2021-03-25 Merck Patent Gmbh Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
CN114423454A (zh) 2019-09-20 2022-04-29 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体的给药
EP4048693A1 (en) 2019-09-27 2022-08-31 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4034560A1 (en) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance antibodies and uses thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
GB201914399D0 (en) 2019-10-04 2019-11-20 Univ Newcastle Biomarkers for assessing explant organ viability
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2021070181A1 (en) 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
US10984211B1 (en) 2019-10-18 2021-04-20 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device with bioFET and biometric sensors
TWI865644B (zh) 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EP4051279A1 (en) 2019-11-01 2022-09-07 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
AU2020378335A1 (en) 2019-11-05 2022-04-07 Merck Patent Gmbh Anti-TIGIT antibodies and uses thereof
EP4054633A1 (en) 2019-11-05 2022-09-14 Merck Patent GmbH Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
AU2020378330A1 (en) 2019-11-06 2022-05-12 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for treatment of hematologic cancers
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
CN114728065A (zh) 2019-11-26 2022-07-08 上海岸迈生物科技有限公司 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
EP4073115A1 (en) 2019-12-09 2022-10-19 Novartis AG Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
US12577324B2 (en) 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof
EP4073117A1 (en) 2019-12-10 2022-10-19 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4073119A1 (en) 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
JP2023506465A (ja) 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN115315256A (zh) 2020-01-27 2022-11-08 基因泰克公司 用抗tigit拮抗剂抗体治疗癌症的方法
WO2021151974A1 (en) 2020-01-28 2021-08-05 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
MX2022009391A (es) 2020-01-31 2022-09-26 Genentech Inc Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
CN113248611B (zh) 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
EP4106767A1 (en) 2020-02-21 2022-12-28 Université de Liège Depletion of ext1 expression and/or activity improves cellular production of biological entities
CA3169959A1 (en) 2020-02-21 2021-08-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-il-4r antibody and use thereof
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
US20230184745A1 (en) 2020-03-05 2023-06-15 Umc Utrecht Holding B.V. Screening method for effective target - E3 ligase combinations
CA3169792A1 (en) 2020-03-05 2021-09-10 Umc Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
JP2023519962A (ja) 2020-03-31 2023-05-15 アレクトル エルエルシー 抗ｍｅｒｔｋ抗体及びその使用方法
CN115667308A (zh) 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
JP2023520587A (ja) 2020-04-06 2023-05-17 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト
CN115698289A (zh) 2020-04-09 2023-02-03 慕尼黑工业大学 定向递送miR-21抑制剂至巨噬细胞用于治疗肺纤维化
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
WO2021214129A1 (en) 2020-04-21 2021-10-28 Université Catholique de Louvain Alpha-2 adrenergic receptor agonists for the treatment of cancer
US20230149360A1 (en) 2020-04-21 2023-05-18 Université Catholique de Louvain Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders
KR20230088306A (ko) 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법
US20230159939A1 (en) 2020-04-22 2023-05-25 Fabmid Methods for circularizing linear double stranded nucleic acids
CA3172880A1 (en) 2020-04-27 2021-11-04 Sotirios Tsimikas Isoform-independent antibodies to lipoprotein(a)
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2021222533A1 (en) 2020-04-30 2021-11-04 Procisedx Inc. Methods of detecting antibodies to sars-cov-2
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
GB202007312D0 (en) 2020-05-18 2020-07-01 Synthetic Vac Ltd Mimotope peptides of the spike protein from the sars-cov-2 virus
CN115667515A (zh) 2020-05-22 2023-01-31 中外制药株式会社 中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体
GB202008651D0 (en) 2020-06-09 2020-07-22 Univ Newcastle Method of identifying complement modulators
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
CN115916348A (zh) 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
US20230014026A1 (en) 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
WO2022009203A1 (en) 2020-07-06 2022-01-13 Technion Research & Development Foundation Limited Heparanase-neutralizing a54 monoclonal antibody
EP4180456A4 (en) 2020-07-09 2024-04-03 Beijing Kawin Technology Share-Holding Co., Ltd. ANTIBODIES BINDING TO HEPATITIS B VIRUS SURFACE ANTIGEN AND APPLICATION OF THE ANTIBODY
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
AU2021313388A1 (en) 2020-07-23 2023-01-19 Erasmus University Medical Center Rotterdam (Erasmus Mc) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
FR3112939B1 (fr) 2020-07-31 2024-01-05 Univ Montpellier Produit universel de thérapie cellulaire et son utilisation
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
WO2022032228A1 (en) 2020-08-07 2022-02-10 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도
WO2022044010A1 (en) 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
CN114106173A (zh) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CR20230146A (es) 2020-09-11 2023-06-07 Medimmune Ltd Moléculas de unión a b7-h4 terapéuticas
FR3114160B1 (fr) 2020-09-11 2026-01-02 Dyameo Rapporteur fluorescent et son utilisation pour la détection de molécules cibles
CA3194182A1 (en) 2020-09-12 2022-03-17 Medimmune Limited A scoring method for an anti-b7h4 antibody-drug conjugate therapy
CN116323674A (zh) 2020-09-21 2023-06-23 基因泰克公司 多特异性抗体的纯化
JP2023542953A (ja) 2020-09-24 2023-10-12 ジェネンテック， インコーポレイテッド 改変された脂肪酸エステル分布を有するポリソルベート混合物
US20230357398A1 (en) 2020-09-24 2023-11-09 Morphosys Ag Novel human antibodies binding to human cd3 epsilon
WO2022074648A1 (en) 2020-10-05 2022-04-14 4C Biomed Limited Marker for response to pd-1/pd-l1 immunotherapy
TW202233672A (zh) 2020-10-22 2022-09-01 美商健生生物科技公司 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
US20230372319A1 (en) 2020-11-02 2023-11-23 Ares Trading S.A. Combination Treatment of Cancer
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combined treatment
CA3200858A1 (en) 2020-11-24 2022-06-02 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
WO2022122654A1 (en) 2020-12-07 2022-06-16 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
US20230416357A1 (en) 2020-12-07 2023-12-28 UCB Biopharma SRL Antibodies against interleukin-22
US20240103016A1 (en) 2020-12-09 2024-03-28 Gynuity Health Projects, Inc. Methods of detecting papp-a and related methods for gestational age assessment
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
US20240092926A1 (en) 2021-01-20 2024-03-21 Oncoresponse, Inc. Immunomodulatory antibodies and uses thereof
US20240270840A1 (en) 2021-02-11 2024-08-15 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
EP4301781A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022187270A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
JP2024508157A (ja) 2021-03-04 2024-02-22 センター ナショナル デ ラ レシェルシェ サイエンティフィーク 炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
IL305758A (en) 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
EP4308157A1 (en) 2021-03-15 2024-01-24 Genentech, Inc. Compositions and methods of treating lupus nephritis
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
MX2023010917A (es) 2021-03-18 2023-09-27 Medimmune Ltd Molecula de union terapeutica que se une a ccr9.
JP2024512002A (ja) 2021-03-18 2024-03-18 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
MX2023011340A (es) 2021-03-26 2023-12-14 Janssen Biotech Inc Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
MX2023011796A (es) 2021-04-09 2024-01-08 Seagen Inc Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit).
CA3235132A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2022226130A1 (en) 2021-04-21 2022-10-27 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
EP4334355A1 (en) 2021-05-03 2024-03-13 UCB Biopharma SRL Antibodies
IL308163A (en) 2021-05-03 2024-01-01 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
TW202300520A (zh) 2021-05-19 2023-01-01 大陸商上海詩健生物科技有限公司 特異性識別baff-r的嵌合抗原受體分子及其應用
WO2022248380A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
WO2022258622A1 (en) 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗ＭｅｒＴＫ抗体及びその使用方法
EP4355352A1 (en) 2021-06-18 2024-04-24 advanceCOR GmbH Use of a pharmaceutical composition
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
IL310437A (en) 2021-07-29 2024-03-01 Inst Nat Sante Rech Med Humanized anti-human βig-h3 protein and uses thereof
EP4384553A1 (en) 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies
TW202328170A (zh) 2021-09-14 2023-07-16 美商艾希利歐發展股份有限公司 可裂解連接子
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
JP2024542939A (ja) 2021-10-15 2024-11-19 リジェネクスバイオ インコーポレイテッド 抗体及びその使用方法
EP4419558A1 (en) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb antibodies and methods of use thereof
WO2023072958A1 (en) 2021-10-25 2023-05-04 Fabmid Methods for circularizing linear double stranded nucleic acids and the products thereof
CN118159517A (zh) 2021-10-27 2024-06-07 基因泰克公司 约束络合剂的合成
JP2024540196A (ja) 2021-10-27 2024-10-31 グラニット バイオ アーゲー Ｃｃｒ２を標的とする抗体
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
KR20240102971A (ko) 2021-11-16 2024-07-03 제넨테크, 인크. 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
EP4453224A1 (en) 2021-12-21 2024-10-30 Universität Zürich Adenoviral vectors
WO2023122665A1 (en) 2021-12-22 2023-06-29 Genentech, Inc. Clinical formulations of anti-tigit antibodies
EP4453034A1 (en) 2021-12-23 2024-10-30 The Broad Institute Inc. Parallel antibody engineering compositions and methods
US20250092158A1 (en) 2022-02-07 2025-03-20 Yeda Research And Development Co. Ltd. Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
IL314634A (en) 2022-02-18 2024-09-01 Adivo Gmbh Feline Antibody Library
EP4482523A1 (en) 2022-02-23 2025-01-01 Alector LLC Methods of use of anti-trem2 antibodies
GB202202569D0 (en) 2022-02-24 2022-04-13 Amlo Biosciences Ltd Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
WO2023164286A1 (en) 2022-02-28 2023-08-31 Xilio Development, Inc. Engineered cd122 compositions and methods thereof
MX2024010488A (es) 2022-02-28 2024-09-05 Xilio Dev Inc Citocinas dirigidas y metodos de uso de estas.
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
TW202345899A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
IL314452A (en) 2022-03-11 2024-09-01 Astrazeneca Ab Scoring method for anti-frα antibody-drug treatment
CN119173532A (zh) 2022-03-11 2024-12-20 詹森药业有限公司 多特异性抗体及其用途
KR20240155353A (ko) 2022-03-11 2024-10-28 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름) B 및 t 세포의 특이적 재프로그래밍을 위한 핵산 시스템 및 이의 용도
EP4490184A1 (en) 2022-03-11 2025-01-15 JANSSEN Pharmaceutica NV Multispecific antibodies and uses thereof
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
US20250206819A1 (en) 2022-03-22 2025-06-26 Morphosys Ag Deimmunized antibodies specific for cd3
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
JP2025510828A (ja) 2022-04-01 2025-04-15 ジェネンテック， インコーポレイテッド ポリペプチドを安定化するためのヒドロキシプロピルメチルセルロース誘導体
TW202340259A (zh) 2022-04-14 2023-10-16 瑞士商諾華公司 抗cd19藥劑之劑量方案及其用途
EP4514472A1 (en) 2022-04-25 2025-03-05 Biond Biologics Ltd. Anti-ilt3 antibodies and use thereof
EP4269432A1 (en) 2022-04-26 2023-11-01 Universite de Rouen Normandie Production of therapeutic antibodies by the microalgae phaeodactylum tricornutum
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
EP4537107A2 (en) 2022-06-07 2025-04-16 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
KR20250034296A (ko) 2022-07-07 2025-03-11 씨메이오 테라퓨틱스 아게 Cd117을 표적화하는 항체
JP2025524656A (ja) 2022-07-14 2025-07-30 ザ・ブロード・インスティテュート・インコーポレイテッド トランスフェリン受容体との相互作用を通じてｃｎｓ全体への遺伝子送達を可能にするａａｖキャプシド
KR20250039361A (ko) 2022-07-15 2025-03-20 실리오 디벨럽먼트, 인크. 담체로서의 조작된 절단성 Fc 도메인 및 이의 사용 방법
TW202415679A (zh) 2022-07-29 2024-04-16 美商阿列克特有限責任公司 抗ｇｐｎｍｂ抗體及其使用方法
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
US20260061078A1 (en) 2022-08-31 2026-03-05 Universität Zürich Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
EP4584291A1 (en) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
US20260035468A1 (en) 2022-09-12 2026-02-05 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
WO2024074649A1 (en) 2022-10-05 2024-04-11 Alcea Therapeutics, Inc. Notch4 antibodies, compositions, and methods for treating airway inflammation
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
US20260103541A1 (en) 2022-10-07 2026-04-16 Universität Zürich Paracrine Adenoviral Delivery of Biomolecules
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024099990A1 (en) 2022-11-07 2024-05-16 Leibniz-Institut Für Immuntherapie (Lit) TGF-ß SWITCH RECEPTOR CAR T CELLS
WO2024102734A1 (en) 2022-11-08 2024-05-16 Genentech, Inc. Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100663A1 (en) 2022-11-10 2024-05-16 Famewave Ltd. Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
CN120202411A (zh) 2022-11-18 2025-06-24 基因泰克公司 使用质量标签进行基于ia-lc-ms/ms的测定的信号放大和多重化
IL320985A (en) 2022-11-28 2025-07-01 Novartis Ag PCTA derivatives, their conjugates and their uses
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
JP2026501236A (ja) 2022-12-20 2026-01-14 ヤンセン バイオテツク，インコーポレーテツド 腫瘍溶解性ウイルス及びその使用
JP2026500540A (ja) 2022-12-23 2026-01-07 シメイオ セラピューティクス アーゲー Ｃｄ４５を標的とする抗体
EP4646270A2 (en) 2023-01-06 2025-11-12 Alector LLC Anti-il18 binding protein antibodies and methods of use thereof
WO2024169990A1 (zh) 2023-02-13 2024-08-22 浙江大学绍兴研究院 双特异性抗体及其应用
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
GB202303531D0 (en) 2023-03-10 2023-04-26 Fusion Antibodies Plc Antibodies and uses thereof
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
EP4688848A1 (en) 2023-03-27 2026-02-11 Zoetis Services LLC Anti-canine pd-l1 antibodies
CN121194989A (zh) 2023-03-30 2025-12-23 272生物有限公司 GnRH结合多肽及其用途
EP4692128A1 (en) 2023-03-31 2026-02-11 Kangma-Healthcode (Shanghai) Biotech Co., Ltd Fusion protein, corresponding nucleic acid, in-vitro synthesis system, and preparation method
WO2024211287A1 (en) 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
WO2024209089A1 (en) 2023-04-07 2024-10-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2024236167A1 (en) 2023-05-17 2024-11-21 Morphosys Ag Il-13 receptor alpha 2 binding polypeptides
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
WO2024245988A1 (en) 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2
KR20260019463A (ko) 2023-06-01 2026-02-10 피에르 파브르 메디카먼트 종양 및 전이의 치료를 위한 침묵화된 항체 기반의 항-met 구조물
CN121285742A (zh) 2023-06-08 2026-01-06 基因泰克公司 用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
EP4725969A1 (en) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
WO2024261027A1 (en) 2023-06-19 2024-12-26 Vector Biopharma Ag Il-7-retargeting of adenoviruses for cell specific infection
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025027472A2 (en) 2023-07-31 2025-02-06 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
CN121712801A (zh) 2023-08-14 2026-03-20 莫佛塞斯有限责任公司 包含空间位阻部分的CyCAT半体分子
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
US20250092109A1 (en) 2023-08-30 2025-03-20 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
WO2025049948A1 (en) 2023-08-30 2025-03-06 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025062392A1 (en) 2023-09-20 2025-03-27 Biond Biologics Ltd. Anti-ilt3 blockade combinations
WO2025061682A1 (en) 2023-09-21 2025-03-27 Universität Zürich Adenoviral targeting of dendritic cells
CN121816366A (zh) 2023-09-27 2026-04-07 百进公司 抗gpc4抗体
WO2025068454A1 (en) 2023-09-28 2025-04-03 Sixpeaks Bio Ag Antibodies targeting actriia and actriib
WO2025076131A1 (en) * 2023-10-03 2025-04-10 Revopsis Therapeutics, Inc. Compostions of multispecific antigen binding polypeptides and methods of use
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
WO2025114411A1 (en) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale New method to treat brain or neurologic disorders
TW202545979A (zh) 2024-01-10 2025-12-01 美商艾希利歐發展股份有限公司 經遮蔽之ｉｌ－２細胞介素及其使用方法
WO2025155923A1 (en) 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025171006A1 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
WO2025186778A1 (en) 2024-03-08 2025-09-12 Janssen Biotech, Inc. Combinations of oncolytic viruses and immunomodulators
WO2025186779A1 (en) 2024-03-08 2025-09-12 Janssen Biotech, Inc. Oncolytic viruses expressing immunomodulators and use for treating advanced solid tumor
WO2025217163A2 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Novel aav capsids binding to human cd59
WO2025217174A1 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025215647A1 (en) 2024-04-11 2025-10-16 Biond Biologics Ltd. Combination cancer treatment with staggered dosing
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025233867A1 (en) 2024-05-10 2025-11-13 Adaptam Therapeutics, S.L. Anti-siglec-9 antibodies and uses thereof
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
TW202547865A (zh) 2024-05-17 2025-12-16 比利時商Ｕｃｂ生物製藥公司 具有il-11結合特異性的抗體
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025242910A1 (en) 2024-05-23 2025-11-27 Egle Therapeutics Il18r agonist antibodies and uses thereof
EP4653460A1 (en) 2024-05-23 2025-11-26 Egle Therapeutics Il18r agonist antibodies and uses thereof
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2026017820A1 (en) 2024-07-18 2026-01-22 Egle Therapeutics Fusion protein for cancer treatment
EP4681780A1 (en) 2024-07-18 2026-01-21 Egle Therapeutics Immunocytokine for cancer treatment
WO2026052977A1 (en) 2024-09-09 2026-03-12 Finn Therapeutics Ltd. Antibodies binding receptor activity-modifying protein (ramp)-3 and uses thereof
WO2026058155A1 (en) 2024-09-11 2026-03-19 Novartis Ag Antibodies targeting il-31
WO2026057740A1 (en) 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules
WO2026072685A1 (en) 2024-09-25 2026-04-02 Genentech, Inc. Compositions and methods of treating lupus nephritis
EP4721765A1 (en) 2024-10-04 2026-04-08 Commissariat à l'Energie Atomique et aux Energies Alternatives Bi-functionalized antibody conjugates against the endothelin receptor b
EP4729126A1 (en) 2024-10-17 2026-04-22 Centre National de la Recherche Scientifique Nk cell-derived extracellular vesicles armed with modified monoclonal antibodies to target cancer cells, and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000098A (en) * 1974-08-16 1976-12-28 Palo Alto Medical Research Foundation Separation of proteins by hydrophobic adsorption
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
DE69232137T2 (de) * 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994013806A1 (en) 1992-12-11 1994-06-23 The Dow Chemical Company Multivalent single chain antibodies
GB9412166D0 (en) 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue

Also Published As

Publication number Publication date
CA2214633A1 (en) 1996-10-24
ATE510854T1 (de) 2011-06-15
DE69636733D1 (de) 2007-01-11
EP0821695B1 (en) 2006-11-29
ATE346858T1 (de) 2006-12-15
CA2214633C (en) 2009-02-24
DE69636733T2 (de) 2007-10-18
JP4091087B2 (ja) 2008-05-28
ES2365929T3 (es) 2011-10-13
NZ334211A (en) 2000-09-29
NZ306718A (en) 1999-04-29
EP1752465B1 (en) 2011-05-25
EP1752465A3 (en) 2008-02-27
PT821695E (pt) 2007-03-30
JPH11504007A (ja) 1999-04-06
EP0821695A1 (en) 1998-02-04
US5641870A (en) 1997-06-24
WO1996033208A1 (en) 1996-10-24
US6214984B1 (en) 2001-04-10
JP2006262906A (ja) 2006-10-05
US20020002271A1 (en) 2002-01-03
AU5534996A (en) 1996-11-07
IL117942A (en) 2000-06-01
EP1752465A2 (en) 2007-02-14
ZA962885B (en) 1997-10-13
JP4042868B2 (ja) 2008-02-06
MX9707909A (es) 1997-11-29
US7038017B2 (en) 2006-05-02
JP2006257098A (ja) 2006-09-28
DK0821695T3 (da) 2007-03-26
JP4153533B2 (ja) 2008-09-24
HK1099310A1 (en) 2007-08-10
US6066719A (en) 2000-05-23
US8012754B2 (en) 2011-09-06
ES2277344T3 (es) 2007-07-01
AU721736B2 (en) 2000-07-13
US20050271654A1 (en) 2005-12-08
IL117942A0 (en) 1996-08-04

Similar Documents

Publication Publication Date Title
ATE510854T1 (de) Lineares, schweres antikörperkettenfragment vh- ch1-vh-ch1
NL300335I1 (nl) Menselijke monoklonale antilichamen tegen epidermale groeifactorreceptor
ATE522609T1 (de) Neurotrophe faktoren
PT733069E (pt) Antigenios ctla-8 de primata purificados e reagentes relacionados
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
FI864427A0 (fi) Menetelmä polypeptidin valmistamiseksi, joka on komplementaarinen ainakin osalle alkuperäistä peptidiä tai proteiinia, ja komplementaarisen polypeptidin käyttö
PT1087013E (pt) Imunoglobtainas desprovidas de cadeias leves
ES2087323T3 (es) Metodo para producir peptidos exentos de cisteina.
DE69133179D1 (de) Katalytische antikörperkomponente
ATE177758T1 (de) Synthetische peptide, antikörper dagegen und ihre verwendung
DE122007000031I1 (de) Für menschliches Papillomavirus stamm 18 kodierende DNS
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ES2061973T3 (es) Anticuerpos monoclonales que reconocen la region n-terminal de polipeptido natriuretico auricular, su preparacion y uso.
ATE83930T1 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
NO930406D0 (no) Spesifikke antistoffer mot aktiverte blodplater samt fremstilling
EA200100110A1 (ru) Нейротрофические факторы
DE69333683D1 (de) Antikörper-testbesteck zur bestimmung von amylin
ATE193021T1 (de) Lipoprotein (a)-peptide und deren verwendung
FI940684L (fi) Menetelmä Streptococcus suis -bakteerin adhesiiniproteiinin ja sen vasta-aineen valmistamiseksi
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
ES2077905T3 (es) Polipeptidos especificos de schizosaccharomyces.